Temporal trends in Human T-Lymphotropic virus 1 (HTLV-1) associated myelopathy/tropical spastic paraparesis (HAM/TSP) incidence in Martinique over 25 years (1986-2010)
- PMID: 29554087
- PMCID: PMC5875895
- DOI: 10.1371/journal.pntd.0006304
Temporal trends in Human T-Lymphotropic virus 1 (HTLV-1) associated myelopathy/tropical spastic paraparesis (HAM/TSP) incidence in Martinique over 25 years (1986-2010)
Abstract
Background: Human T-lymphotropic virus type 1 (HTLV-1) has been discovered in 1980 and has been linked to tropical spastic paraparesis (HAM/TSP) in 1985 in Martinique. There is no data on HAM/TSP incidence trends. We report, in the present work, the temporal trends incidence of HAM/TSP in Martinique over 25 years.
Methods: Martinique is a Caribbean French West Indies island deserved by a unique Neurology Department involved in HAM/TSP diagnosis and management. A registry has been set up since 1986 and patients diagnosed for a HAM/TSP were prospectively registered. Only patients with a definite HAM/TSP onset between 1986 and 2010 were included in the present study. The 25-year study time was stratified in five-year periods. Crude incidence rates with 95% confidence interval (95%CI) were calculated using Poisson distribution for each period. Age-standardized rates were calculated using the direct method and the Martinique population census of 1990 as reference. Standardized incidence rate ratios with 95% CIs and P trends were assessed from simple Poisson regression models. Number of HTLV-1 infection among first-time blood donors was retrospectively collected from the central computer data system of the Martinique blood bank. The HTLV-1 seroprevalence into this population has been calculated for four 5-year periods between 1996 and 2015.
Results: Overall, 153 patients were identified (mean age at onset, 53+/-13.1 years; female:male ratio, 4:1). Crude HAM/TSP incidence rates per 100,000 per 5 years (95%CI) in 1986-1990, 1991-1995, 1996-2000, 2001-2005 and 2006-2010 periods were 10.01 (6.78-13.28), 13.02 (9.34-16.70), 11.54 (8.13-14.95), 4.27 (2.24-6.28) and 2.03 (0.62-3.43). Age-standardized 5-year incidence rates significantly decreased by 69% and 87% in 2001-2005 and 2006-2010 study periods. Patients characteristics did not differ regarding 1986-2000 and 2001-2010 onset periods. Between 1996-2000 and 2011-2015 study periods, the HTLV-1 seroprevalence significantly decreased by 63%.
Conclusion: Martinique faces a sudden and rapid decline of HAM/TSP incidence from 2001 in comparison to 1986-2000 periods. Reduction of HTLV-1 seroprevalence, that may result from transmission prevention strategy, could account for HAM/TSP incidence decrease.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
Incidence of human T cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis in a long-term prospective cohort study of initially asymptomatic individuals in Brazil.AIDS Res Hum Retroviruses. 2013 Sep;29(9):1199-202. doi: 10.1089/aid.2013.0086. Epub 2013 May 31. AIDS Res Hum Retroviruses. 2013. PMID: 23617363
-
Anti-HTLV antibody profiling reveals an antibody signature for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).Retrovirology. 2008 Oct 20;5:96. doi: 10.1186/1742-4690-5-96. Retrovirology. 2008. PMID: 18937847 Free PMC article.
-
Presence of tropical spastic paraparesis/human T-cell lymphotropic virus type 1-associated myelopathy (TSP/HAM)-like among HIV-1-infected patients.J Med Virol. 2008 Mar;80(3):392-8. doi: 10.1002/jmv.21111. J Med Virol. 2008. PMID: 18205234
-
Tropical spastic paraparesis and HTLV-1 associated myelopathy: clinical, epidemiological, virological and therapeutic aspects.Rev Neurol (Paris). 2012 Mar;168(3):257-69. doi: 10.1016/j.neurol.2011.12.006. Epub 2012 Mar 7. Rev Neurol (Paris). 2012. PMID: 22405461 Review.
-
HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP): the role of HTLV-I-infected Th1 cells in the pathogenesis, and therapeutic strategy.Folia Neuropathol. 2009;47(2):182-94. Folia Neuropathol. 2009. PMID: 19618340 Review.
Cited by
-
Latency Reversing Agents: Kick and Kill of HTLV-1?Int J Mol Sci. 2021 May 24;22(11):5545. doi: 10.3390/ijms22115545. Int J Mol Sci. 2021. PMID: 34073995 Free PMC article. Review.
-
Human T cell leukemia virus type 1 and Zika virus: tale of two reemerging viruses with neuropathological sequelae of public health concern.J Neurovirol. 2019 Jun;25(3):289-300. doi: 10.1007/s13365-019-00720-7. Epub 2019 Jan 28. J Neurovirol. 2019. PMID: 30693421 Review.
-
HTLV-1-Associated Myelopathy (HAM) Incidence in Asymptomatic Carriers and Intermediate Syndrome (IS) Patients.Pathogens. 2024 May 13;13(5):403. doi: 10.3390/pathogens13050403. Pathogens. 2024. PMID: 38787255 Free PMC article.
-
Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan.Orphanet J Rare Dis. 2019 Oct 21;14(1):227. doi: 10.1186/s13023-019-1212-4. Orphanet J Rare Dis. 2019. PMID: 31639014 Free PMC article.
-
Incidence of HTLV-1-associated myelopathy in the UK from 1991 to 2024: a longitudinal observational cohort study.Front Med (Lausanne). 2025 Jan 7;11:1519750. doi: 10.3389/fmed.2024.1519750. eCollection 2024. Front Med (Lausanne). 2025. PMID: 39839639 Free PMC article.
References
-
- de The G., and Bomford R (1993) An HTLV-I vaccine: why, how, for whom? AIDS Res. Hum. Retroviruses 9:381–386. - PubMed
-
- Hlela C, Shepperd S, Khumalo NP, Taylor GP (2009) The prevalence of human T-cell lymphotropic virus type 1 in the general population is unknown. AIDS Rev 1:205–14. - PubMed
-
- Manns A, Wilks RJ, Murphy EL, Haynes G, Figueroa JP, Barnett M, et al. (1992) A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer 51:886–91. - PubMed
-
- Donegan E, Lee H, Operskalski EA, Shaw GM, Kleinman SH, Busch MP et al. (1994) Transfusion transmission of retroviruses: human T-lymphotropic virus types I and II compared with human immunodeficiency virus type 1. Transfusion 34:478–83. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous